Clinical Trial Update: A Vaccine (H2NVAC) Before Surgery for the Treatment of HER2-Expressing Ductal Carcinoma In Situ [Phase 1]

View source ↗

Summary

Phase 1 clinical trial evaluating H2NVAC, a vaccine, before surgery for HER2-expressing ductal carcinoma in situ of the breast; study currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ductal Carcinoma in Situ of the Breast

Drugs mentioned

• H2NVAC (H2NVAC)

Snippet

Sponsor: Mayo Clinic | Conditions: Breast Ductal Carcinoma In Situ | Phase 1 | Status: RECRUITING